Provided by Tiger Trade Technology Pte. Ltd.

Cortexyme Inc.

1.95
0.0000
Volume:- -
Turnover:521.88K
Market Cap:70.49M
PE:-0.66
High:1.95
Open:1.95
Low:1.95
Close:1.95
52wk High:121.98
52wk Low:1.78
Shares:36.15M
Float Shares:24.77M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9635
EPS(LYR):-3.0266
ROE:-67.34%
ROA:-37.49%
PB:0.66
PE(LYR):-0.64

Loading ...

Company Profile

Company Name:
Cortexyme Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.